---
title: 'Director, Commercial Data, Advanced Analytics & Forecasting at REGENXBIO'
canonical: 'https://feeny.ai/job/director-commercial-data-advanced-analytics-forecasting-regenxbio-remote-88y6fvc5kv5j'
type: 'job'
last_seen: '2026-09-14'
---

# Director, Commercial Data, Advanced Analytics & Forecasting at REGENXBIO

- **Company:** REGENXBIO
- **Location:** Remote
- **Employment:** full-time
- **Work type:** remote
- **Posted:** 2026-09-11
- **Last confirmed live:** 2026-09-14
- **Apply:** https://jobs.lever.co/regenxbio/5adcad30-6a08-47ea-beb9-3d957ddf9eb5

## Job description

Since our founding in 2009, REGENXBIO has pioneered what's possible in gene therapy. Today, we are advancing a pipeline of gene therapies designed to improve the lives of patients facing serious rare and retinal diseases and preparing to bring innovative new medicines to patients. Our work is fueled by purpose and urgency because every day matters to patients and their families. If you're looking for meaningful work, opportunities to grow, and the chance to help bring potentially transformative gene therapies to patients, we'd love to hear from you. What we do matters.

The Opportunity

As the Director, Commercial Data, Advanced Analytics & Forecasting, you will build and lead the data, advanced analytics, and forecasting capabilities needed to ensure launch readiness and guide commercial decision-making. This individual will play a critical role in translating brand strategy into decision and analytics framework, develop advanced analyses and patient-based forecasts, and turn complex data into decision-ready insights and KPIs.

## How You’ll Contribute

- Design measurement frameworks that connect market development, customer engagement, field execution, account readiness, patient progression, access, treatment, and business outcomes.
- Build advanced analyses and decision-support models to identify leading indicators and early-warning signals that enable action before risks or opportunities are evident in lagging performance measures.
- Lead analytics across market sizing, patient identification, customer segmentation and targeting, referral networks, payer access, field-force optimization, territory potential, and launch performance.
- Translate complex analytical findings into clear recommendations, implications, risks, and actions for senior executives and operating teams.
- Own patient-based, demand, launch, and long-range commercial forecasting, incorporating drivers such as epidemiology, diagnosis, patient identification and eligibility, referral, treatment-center capacity, access, time to treatment, uptake, competitive dynamics, and supply considerations.
- Build key scenarios, including base, upside/downside, label, and access scenarios
- Monitor actual performance versus assumptions
- Identify, evaluate, and manage relevant data sources, including HCP, payer, claims, prescription, account, CRM, patient services, hub, specialty pharmacy, specialty distributor, shipment, digital, financial, epidemiology, market research, and competitive intelligence data.
- Oversee data ingestion, integration, customer and account master data, and aggregation processes to deliver accurate, high-quality, analytics-ready datasets.
- Develop and maintain dashboards, reports, scorecards, and KPI-tracking tools, and support recurring business reviews using Power BI, Tableau, Excel, and other business intelligence platforms.
- Develop a practical, governed roadmap for commercial AI, machine learning, generative AI, and analytical automation.

What You’ll Bring:

- Bachelor’s degree in statistics, mathematics, computer science, or a related quantitative discipline; relevant advanced degree strongly preferred.
- 10+ years of progressive experience in commercial analytics, data science, forecasting, business intelligence, commercial operations, or a related function within pharmaceuticals, biotechnology, or healthcare.
- Direct experience supporting at least one U.S. product launch from pre-launch planning through launch or early commercialization.
- Advanced, hands-on SQL proficiency required, including the ability to independently extract, join, transform, validate, and analyze complex datasets.
- Strong hands-on capability in at least one of Python, R, SAS, Alteryx, or a comparable analytical platform.
- Strong proficiency with Excel and business-intelligence or visualization tools such as Power BI or Tableau.
- Demonstrated experience building advanced analytical models, customer or account segmentations, targeting analyses, field-effectiveness analyses, and decision-support tools.
- Demonstrated experience developing and maintaining patient-based, demand, launch, or long-range forecasts.
- Experience working with healthcare-provider, payer, claims, CRM, patient-services, specialty-pharmacy, specialty-distributor, shipment, financial, market-research, or other complex commercial datasets.
- Experience defining requirements for data acquisition, data integration, data warehouses or lakehouses, data aggregation, analytics-ready datasets, data quality, metadata, lineage, and governance.
- Working knowledge of statistical modeling, predictive analytics, machine learning, AI, and analytical automation.
- Ability to translate Brand strategy into analytical questions, data requirements, models, KPIs, insights, and commercial actions.
- Willingness and ability to travel up to 25%.

## What You Can Expect

At REGENXBIO, we're committed to fostering an environment where people can do meaningful work, grow professionally, and make an impact. Our core values – trust, accountability, perseverance, and innovation – drive everything we do.

We offer a comprehensive and competitive benefit & compensation package which includes market-competitive salaries, an annual bonus program, education assistance, paid caregiver leave, retirement plan with employer match, stock options at all levels, summer hours and more! The estimated compensation range for this role is $196,000 to $265,000 annually. The actual salary offered to the final candidate depends on a number of factors such as relevant work experience, skills, education, and years of experience.

## About REGENXBIO

## Company Overview
- **One-liner**: REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for rare and retinal diseases using its proprietary AAV vector platform.
- **Entity Type**: Public (NASDAQ: RGNX)
- **Headquarters**: Rockville, Maryland, United States
- **Founded**: 2008 (founded as a company; operations began in 2009)
- **Founders**: Not publicly listed as individual founders; the company was spun out from the gene therapy research of the University of Pennsylvania and licensed its NAV Technology Platform from the university.

## Core Business
- **Primary industry**: Biotechnology – Gene Therapy (AAV-based)
- **Target customers**: B2B (pharma partners like AbbVie, Nippon Shinyaku) and B2G (regulatory agencies, clinical trial sites); ultimate customers are patients with rare and retinal diseases (Duchenne muscular dystrophy, MPS I, MPS II, wet AMD, diabetic retinopathy).
- **Mission or purpose statement**: “To improve lives through the curative potential of gene therapy.” [regenxbio.com](https://www.regenxbio.com/culture-careers/)

## Products & Services
- **NAV® Technology Platform**: Proprietary AAV vector gene delivery platform (including AAV8 and AAV9) used for internal programs and licensed to partners (e.g., Novartis for ZOLGENSMA®).
- **ABBV-RGX-314** (in collaboration with AbbVie): Investigational one-time gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). In pivotal clinical trials.
- **RGX-202** (Duchenne muscular dystrophy): Phase I/II/III AFFINITY DUCHENNE® trial; pivotal phase expected to support BLA submission in 2026 using accelerated approval pathway. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
- **RGX-121** (MPS II – Hunter syndrome): In partnership with Nippon Shinyaku; late-stage development.
- **RGX-111** (MPS I – Hurler syndrome): In partnership with Nippon Shinyaku; clinical development.
- **Manufacturing**: In-house cGMP production facility (REGENXBIO Manufacturing Innovation Center – RMIC) in Rockville, MD, operational since mid-2022.

## Market Standing
- **Valuation/Market Cap**: $447.8 million (as of recent data). [linkedin.com](https://linkedin.com/company/regenx)
- **Key Metric**: Annual Revenue $170.4 million (primarily from license and collaboration revenue). [linkedin.com](https://linkedin.com/company/regenx)
- **Notable Investors/Partners**:
    - AbbVie (collaboration for ABBV-RGX-314)
    - Nippon Shinyaku (partnerships for RGX-121 and RGX-111)
    - Novartis (licensee for ZOLGENSMA® using NAV vectors)
- **Growth Signals**:
    - Headcount: 296 employees (+1.3% YoY). [linkedin.com](https://linkedin.com/company/regenx)
    - BLA submission for RGX-202 targeted for 2026.
    - RMIC facility operational since 2022, enabling scalable clinical and commercial manufacturing.
    - Scholarly output: 160 works, 7,337 citations, field-weighted citation impact of 2.6 (highly influential). [linkedin.com](https://linkedin.com/company/regenx)

## Competitive Advantages
- **Proprietary NAV Technology Platform**: Exclusive rights to a large portfolio of AAV vectors (including AAV8 and AAV9), the foundation for multiple approved and investigational gene therapies. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
- **End-to-end capabilities**: Integrated in-house R&D, preclinical development, clinical development, and cGMP manufacturing.
- **Proven platform**: Thousands of patients have been treated with AAV vectors from the NAV platform (including via Novartis’ ZOLGENSMA®).
- **Late-stage pipeline**: Multiple programs in pivotal or near-pivotal trials (RGX-202, ABBV-RGX-314) with clear regulatory pathways.

## Strategic Focus
- **Near-term**: Advance RGX-202 toward BLA submission in 2026; continue pivotal trials for ABBV-RGX-314 in wet AMD and diabetic retinopathy.
- **Long-term**: Expand pipeline in retinal, neuromuscular, and neurodegenerative diseases; leverage RMIC for commercial-scale manufacturing; deepen partnerships with AbbVie and Nippon Shinyaku.
- **Platform expansion**: Ongoing research to expand NAV vector capabilities and develop new AAV-based therapies.

## Why Work Here
- **Mission-driven culture**: “Patient-focused, driven by results, fosters collaboration.” Core values emphasize accountability, innovation, and serving patients with limited therapeutic options. [regenxbio.com](https://www.regenxbio.com/culture-careers/)
- **Impactful work**: Opportunity to work on one-time gene therapies that could fundamentally alter the course of devastating diseases.
- **Growth & stability**: Public company with late-stage pipeline, strong partnerships, and a clear path to commercialization.
- **Location & facilities**: Headquarters in Rockville, MD, with a state-of-the-art cGMP manufacturing facility (RMIC) on site.
- **Work policy**: Not explicitly stated as remote/hybrid; positions appear to be on-site (based on job listings in Rockville and field-based Medical Science Liaison roles).
- **Perks**: Comprehensive and competitive benefits for employees and families. [regenxbio.com](https://www.regenxbio.com/culture-careers/)
- **Engineering & science culture**: High scholarly output and citation impact; emphasis on cross-functional collaboration between research, manufacturing, and clinical teams.
- **Recruitment note**: REGENXBIO warns of fraudulent job offers; all applications go through their official Lever portal. [regenxbio.com](https://www.regenxbio.com/culture-careers/)

## Sources
1. [regenxbio.com – Culture & Careers](https://www.regenxbio.com/culture-careers/)
2. [linkedin.com – REGENXBIO company page](https://linkedin.com/company/regenx)
3. [ir.regenxbio.com – 10-K Filing (Business Overview)](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
4. [ir.regenxbio.com – Investor Overview](https://ir.regenxbio.com/investor-overview)
5. [jobs.lever.co – REGENXBIO careers](https://jobs.lever.co/regenxbio)

## Other roles at REGENXBIO

- [Associate Director, People Business Partner](https://feeny.ai/job/associate-director-people-business-partner-regenxbio-rockville-fmx3gbzx681y) — Rockville, MD
- [Market Development Director - Southeast Region](https://feeny.ai/job/market-development-director-southeast-region-regenxbio-remote-b1hhp987p5v1)
- [Associate Director, Rare Disease Product Marketing](https://feeny.ai/job/associate-director-rare-disease-product-marketing-regenxbio-rockville-r2p05phcvmx8) — Rockville, MD
- [Associate Director, Data & Information Architecture](https://feeny.ai/job/associate-director-data-information-architecture-regenxbio-rockville-b0m5vrmrm33p) — Rockville, MD
- [Senior Medical Science Liaison - DMD/Neuromuscular (South)](https://feeny.ai/job/senior-medical-science-liaison-dmd-neuromuscular-south-regenxbio-remote-4qggqdykm9ym)
- [Senior Medical Science Liaison - DMD/Neuromuscular (Northeast)](https://feeny.ai/job/senior-medical-science-liaison-dmd-neuromuscular-northeast-regenxbio-remote-47qpcgnnyhpc)
- [Senior Medical Science Liaison - DMD/Neuromuscular (West Coast)](https://feeny.ai/job/senior-medical-science-liaison-dmd-neuromuscular-west-coast-regenxbio-west-coast-yerem2kwy7ca) — West Coast
- [Senior Director, Global Program Development Lead - DMD/Neuromuscular](https://feeny.ai/job/senior-director-global-program-development-lead-dmd-neuromuscular-regenxbio-xbereeg0zrc8) — Rockville, MD
- [Senior Director/Director, Medical Science Liaisons (Neuromuscular/DMD)](https://feeny.ai/job/senior-director-director-medical-science-liaisons-neuromuscular-dmd-regenxbio-aeca83gb75e2)